title: Response to: Long-term trials of pregabalin and duloxetine for fibromyalgia symptoms: How study designs can affect placebo factors.
authors.affiliation: Nuffield Department of Anaesthetics, University of Oxford, Level 6, West Wing, John Radcliffe Hospital, Oxford OX3 9DU, UK.
authors.forename: R A
authors.initials: RA
authors.lastname: Moore
authors.forename: S
authors.initials: S
authors.lastname: Derry
authors.forename: H J
authors.initials: HJ
authors.lastname: McQuay
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage; D000700:Analgesics / Q000008:administration & dosage; D002985:Clinical Protocols; D002986:Clinical Trials as Topic / Q000379:methods*; D000068736:Duloxetine Hydrochloride; D005356:Fibromyalgia / Q000188:drug therapy*; D006801:Humans; D008137:Longitudinal Studies; D017063:Outcome Assessment, Health Care / Q000379:methods*; D015990:Placebo Effect; D000069583:Pregabalin; D013876:Thiophenes / Q000008:administration & dosage*; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000700:Analgesics; D013876:Thiophenes; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D000068736:Duloxetine Hydrochloride
references.citation: Staud R, Price DD. Long-term trials of pregabalin and duloxetine for fibromyalgia symptoms: how study designs can affect placebo factors. Pain. 2008;136:232-234.
references.citation: McQuay HJ, Derry S, Moore RA, Poulain P, Legout V. Enriched enrolment with randomised withdrawal (EERW): time for a new look at clinical trial design in chronic pain. Pain. 2008;135:217-220.
references.citation: Crofford LJ, Mease PJ, Simpson SL, Young JP Jr, Martin SA, Haig GM, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136:419-431.
references.citation: Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136:432-444.
references.citation: Kaptchuk TJ, Stason WB, Davis RB, Legedza AR, Schnyer RN, Kerr CE, et al. Sham device v inert pill: randomised controlled trial of two placebo treatments. BMJ. 2006;332:391-397.
references.citation: Rief W, Avorn J, Barsky AJ. Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. Arch Intern Med. 2006;166:155-160.
references.citation: Meyer FP, Tröger U, Röhl FW. Adverse nondrug reactions: an update. Clin Pharm Ther. 1996;60:347-352.
references.citation: Demyttenaere K, Albert A, Mesters P, Dewé W, De Bruyckere K, Sangeleer M. What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? J Clin Psychiatry. 2005;66:859-863.
references.citation: Meyer FP, Tröger U, Röhl FW. Reliability of symptom reports by healthy volunteers treated with placebo over several time periods. Arzneimittelforschung. 2000;50:768-771.